Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …

The antitumour activity of endogenous or adoptively transferred tumour-specific T cells is
highly dependent on their differentiation status. It is now apparent that less differentiated T …

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …

Adoptive cell therapy with T cells reprogrammed to express chimeric antigen receptors (CAR-
T cells) has been highly successful in patients with hematological neoplasms. However, its …

Chimeric antigen receptor (CAR) T cells have achieved true clinical success in treating
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …

CD8+ T cells are important in protective immunity against intracellular pathogens and
tumors. In chronic infections or cancer, CD8+ T cells are constantly exposed to antigens and …

Genetic redirection of T lymphocytes with chimeric antigen receptors (CARs) has soared
from treating cancers preclinically to FDA approval for hematologic malignancies and …

Interleukin (IL)-2 and IL-21 dichotomously shape CD8+ T cell differentiation. IL-2 drives
terminal differentiation, generating cells that are poorly effective against tumors, whereas IL …

Chimeric antigen receptor T cell (CAR-T cell) therapy is a relatively new, effective, and
rapidly evolving therapeutic for adoptive immunotherapies. Although it has achieved …